Centro de Investigaciones sobre Porfirinas y Porfirias (CIPYP), CONICET and Hospital de Clínicas José de San Martín, Universidad de Buenos Aires, Córdoba 2351 1er subsuelo, CP1120AAF, Buenos Aires, Argentina.
Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Haya de la Torre y Medina Allende, Ciudad Universitaria, Córdoba, Argentina.
Sci Rep. 2021 Dec 10;11(1):23820. doi: 10.1038/s41598-021-03339-z.
Photodynamic therapy (PDT) is an anticancer treatment involving administration of a tumour-localizing photosensitizer, followed by activation by light of a suitable wavelength. In previous work, we showed that the natural anthraquinone (AQ) Parietin (PTN), was a promising photosensitizer for photodynamic therapy of leukemic cells in vitro. The present work aimed to analyze the photosensitizing ability of PTN in the mammary carcinoma LM2 cells in vitro and in vivo in a model of subcutaneously implanted tumours. Photodynamic therapy mediated by parietin (PTN-PDT) (PTN 30 µM, 1 h and 1.78 J/cm of blue light) impaired cell growth and migration of LM2 cells in vitro. PTN per se induced a significant decrease in cell migration, and it was even more marked after illumination (migration index was 0.65 for PTN and 0.30 for PTN-PDT, *p < 0.0001, ANOVA test followed by Tukey's multiple comparisons test), suggesting that both PTN and PTN-PDT would be potential inhibitors of metastasis. Fluorescence microscopy observation indicated cytoplasmic localization of the AQ and no fluorescence at all was recorded in the nuclei. When PTN (1.96 mg) dissolved in dimethyl sulfoxide was topically applied on the skin of mice subcutaneously implanted with LM2 cells, PTN orange fluorescence was strongly noticed in the stratum corneum and also in the inner layers of the tumour up to approximately 5 mm. After illumination with 12.74 J/cm of blue light, one PDT dose at day 1, induced a significant tumour growth delay at day 3, which was not maintained in time. Therefore, we administered a second PTN-PDT boost on day 3. Under these conditions, the delay of tumour growth was 28% both on days 3 and 4 of the experiment (*p < 0.05 control vs. PTN-PDT, two-way ANOVA, followed by Sidak's multiple comparisons test). Histology of tumours revealed massive tumour necrosis up to 4 mm of depth. Intriguingly, a superficial area of viable tumour in the 1 mm superficial area, and a quite conserved intact skin was evidenced. We hypothesize that this may be due to PTN aggregation in contact with the skin and tumour milieu of the most superficial tumour layers, thus avoiding its photochemical properties. On the other hand, normal skin treated with PTN-PDT exhibited slight histological changes. These preliminary findings encourage further studies of natural AQs administered in different vehicles, for topical treatment of cutaneous malignancies.
光动力疗法(PDT)是一种涉及肿瘤定位光敏剂给药,然后用光激活合适波长的抗癌治疗方法。在之前的工作中,我们表明天然蒽醌(AQ)Parietin(PTN)是体外白血病细胞光动力治疗的一种很有前途的光敏剂。本研究旨在分析 PTN 在皮下植入肿瘤模型中体外和体内的乳腺癌细胞 LM2 中的光敏能力。蒽醌光动力疗法介导的帕里丁(PTN-PDT)(PTN 30 μM,1 小时和 1.78 J/cm 的蓝光)可损害 LM2 细胞的生长和迁移。PTN 本身就显著降低了细胞迁移率,而光照后更为显著(PTN 的迁移指数为 0.65,PTN-PDT 为 0.30,*p<0.0001,方差分析后 Tukey 多重比较检验),表明 PTN 和 PTN-PDT 均可能是转移的抑制剂。荧光显微镜观察表明 AQ 定位于细胞质,核内无荧光。当 1.96 mg 溶于二甲基亚砜的 PTN 局部应用于皮下植入 LM2 细胞的小鼠皮肤时,PTN 橙色荧光在角质层和肿瘤内层中强烈可见,可达约 5mm。用 12.74 J/cm 的蓝光照射后,第 1 天接受 1 次 PDT 剂量,第 3 天肿瘤生长明显延迟,且未持续。因此,我们在第 3 天进行了第二次 PTN-PDT 增强治疗。在这些条件下,第 3 天和第 4 天的肿瘤生长延迟分别为 28%(*p<0.05,对照组与 PTN-PDT 比较,双向方差分析,随后 Sidak 多重比较检验)。肿瘤组织学显示最大可达 4mm 深度的肿瘤坏死。有趣的是,在 1mm 的浅层区域有一个存活肿瘤的浅层区域,并且皮肤完好无损。我们假设这可能是由于 PTN 在与皮肤和最浅层肿瘤层的肿瘤环境接触时聚集,从而避免了其光化学性质。另一方面,用 PTN-PDT 处理的正常皮肤显示出轻微的组织学变化。这些初步发现鼓励进一步研究不同载体中天然 AQ 的应用,用于皮肤恶性肿瘤的局部治疗。